Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

Eur Heart J. 2025 Mar 13;46(11):1074-1077. doi: 10.1093/eurheartj/ehae864.

João Pedro Ferreira^{1

2

3}, Faiez Zannad³, Francisco Vasques-Nóvoa^{1

4}, João Sérgio Neves^{1

5}, Gerasimos Filippatos⁶, Stuart J Pocock⁷, Javed Butler^{8

9}, Milton Packer^{10

11}, Stefan D Anker^{12

13}

¹ UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Alameda Prof. Hernâni Monteiro, Porto 4200-319, Portugal.
² Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar de Vila Nova de Gaia, Espinho, Portugal.
³ Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
⁴ Internal Medicine Department, Centro Hospitalar Universitário de São João, Porto, Portugal.
⁵ Endocrinology Department, Centro Hospitalar Universitário de São João, Porto, Portugal.
⁶ National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
⁷ London School of Hygiene and Tropical Medicine, London, UK.
⁸ Baylor Scott and White Research Institute, Dallas, TX, USA.
⁹ University of Mississippi, Jackson, MS, USA.
¹⁰ Baylor Heart and Vascular Institute, Dallas, TX, USA.
¹¹ Imperial College, London, UK.
¹² Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹³ Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland.

No abstract available

Keywords: Anaemia; Empagliflozin; Erythrocytosis; Heart failure with preserved ejection fraction.

Grants and funding